Phase I Multiple Ascending Dose Trial of the MT Stabilizer TPI-287 for Alzheimer Disease (AD)

Investigator: Adam Boxer, MD, PhD
Sponsor: Alzheimer's Association, Inc.

Location(s): United States


The purpose of the study is to determine the highest dose of TPI-287 that is safe and tolerable when administered as an intravenous infusion to participants with mild to moderate Alzheimer's disease (AD), to measure pharmacokinetic properties of the drug as well as to gauge preliminary efficacy of TPI-287 ondisease progression.